Previous 10 | Next 10 |
2024-03-28 10:43:38 ET More on 4D Molecular Therapeutics 4D Molecular Therapeutics Advances Wet AMD Treatment Paradigm 4D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024 Goldman reinstates buy rating on 4D Molecular, cites upcoming catalysts ...
Conducted initial pivotal study interactions with the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA); Company has clear registration path for 4D-710 for treatment of cystic fibrosis (CF) lung disease in people with CF (pwCF) who are ineligible for or cannot tolerate a...
Presented positive interim data from randomized Dose Expansion cohort of the Phase 2 PRISM study evaluating 4D-150 in wet AMD patients with severe disease activity and high treatment burden, enabling advancement into Phase 3 pivotal development, with initiation expected in Q1 2025 Positiv...
2024-02-20 05:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-02-19 20:42:02 ET Summary Age-related macular degeneration (AMD) is a leading cause of vision loss and blindness, with wet AMD being a more severe form. Current treatment for wet AMD involves frequent anti-VEGF injections, but there is a need for therapies with less frequent ...
4D-310 demonstrated clinically meaningful cardiac endpoint improvements through 12-24 months in contractility (echocardiography), peak VO 2 (cardiopulmonary exercise testing) and/or cardiac quality of life (KCCQ) in all five evaluable patients Cardiac biopsies were obtained fr...
2024-02-11 04:27:27 ET Summary Ocular Therapeutix is using its Elutyx technology to develop drug candidates for eye disorders, with upcoming results from the HELIOS study for diabetic retinopathy Q2 2024. The company is also progressing with the phase 3 SOL study for wet age-relat...
2024-02-09 08:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-02-08 18:40:34 ET More on 4D Molecular Therapeutics 4D Molecular Therapeutics Advances Wet AMD Treatment Paradigm 4D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024 4D Molecular Therapeutics up 3%, prices $300M equity Biggest sto...
2024-02-07 05:50:15 ET More on 4D Molecular Therapeutics 4D Molecular Therapeutics Advances Wet AMD Treatment Paradigm 4D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024 4D Molecular stock jumps after positive interim data for eye disease dru...
News, Short Squeeze, Breakout and More Instantly...
4D Molecular Therapeutics Inc. Company Name:
FDMT Stock Symbol:
NASDAQ Market:
4D Molecular Therapeutics Inc. Website:
NEW YORK, NY / ACCESSWIRE / July 21, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of 4D Molecular Therapeutics, Inc. ("4D Molecular" or "the Company") (NASDAQ:FDMT). Investors who purchased 4D Molecular securities are encouraged to obtai...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 6.6% to $117.99 on volume of 383,510,118 shares Aptevo Therapeutics Inc. (APVO) rose 73.4% to $0.581 on volume of 315,289,581 shares PROSHARES TRUST (SQQQ) rose 8.7% to $8.11 on volume of 173,682,364 sha...
Robust reduction in anti-VEGF injection treatment burden through Week 24 achieved in 30 patients at planned Phase 3 dose (3E10 vg/eye) with 89% reduction in annualized injection rate; 93% of patients received 0 or 1 injection and 77% were injection-free Improvement in mean best corr...